Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sight Sciences, Inc.SGHT · Entity 5537 | Director · 10% owner | June 10, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sight Sciences, Inc.
Report date June 10, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,434,283 |
Reported balance
After 2026-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-10 · Purchase · Acquired 14,100 · Balance 1,434,283 F1: The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased in multiple transactions at per share prices ranging from $4.78 to $4.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Includes (i)1,406,022 shares of Common Stock and (ii) 28,261 restricted stock units, which restricted stock units are subject to vesting as previously reported. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 632,456 |
Reported balance
Holding disclosure · report date 2026-06-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 632,456 F3: These shares of Common Stock are held of record by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust (the "Trust"). The Reporting Person is a trustee of the Trust and may be deemed to beneficially own the shares held by the Trust for purposes of Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"). The Reporting Person disclaims beneficial ownership of the shares held by the Trust (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 under the Exchange Act or for any other purpose), except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 5,086,920 |
Reported balance
Holding disclosure · report date 2026-06-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,086,920 F4: These shares of Common Stock are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the Chairman and CEO and sole director of Allegro Investment Inc., which is the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund for purposes of Rule 13d-3 under the Exchange Act. However, the Reporting Person does not have any pecuniary interest in the shares held by Allegro Investment Fund and disclaims beneficial ownership with respect to all such shares. Accordingly, these shares are being reported in this report voluntarily by the Reporting Person for informational purposes only and shall not be deemed an admission that the Reporting Person is the beneficial owner of any such shares for purposes of Section 16 under the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased in multiple transactions at per share prices ranging from $4.78 to $4.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: Includes (i)1,406,022 shares of Common Stock and (ii) 28,261 restricted stock units, which restricted stock units are subject to vesting as previously reported.
F3: These shares of Common Stock are held of record by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust (the "Trust"). The Reporting Person is a trustee of the Trust and may be deemed to beneficially own the shares held by the Trust for purposes of Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"). The Reporting Person disclaims beneficial ownership of the shares held by the Trust (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 under the Exchange Act or for any other purpose), except to the extent of his pecuniary interest therein, if any.
F4: These shares of Common Stock are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the Chairman and CEO and sole director of Allegro Investment Inc., which is the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund for purposes of Rule 13d-3 under the Exchange Act. However, the Reporting Person does not have any pecuniary interest in the shares held by Allegro Investment Fund and disclaims beneficial ownership with respect to all such shares. Accordingly, these shares are being reported in this report voluntarily by the Reporting Person for informational purposes only and shall not be deemed an admission that the Reporting Person is the beneficial owner of any such shares for purposes of Section 16 under the Exchange Act or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 11, 2026 20:43 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 14,100 | $4.88 | $68,793.90 |
DisclosureSEC source: 0001193125-26-267752 · ownership.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,434,283 F1 · price: The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased in multiple transactions at per share prices ranging from $4.78 to $4.93 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Includes (i)1,406,022 shares of Common Stock and (ii) 28,261 restricted stock units, which restricted stock units are subject to vesting as previously reported. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:10 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 28,261 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-259570 · ownership.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,420,183 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2 · balance_after: Includes (i)1,391,922 shares of Common Stock and (ii) 28,261 RSUs which are subject to vesting as reported herein. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 23:10 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 13,958 | $8.31 | $115,963.06 |
DisclosureSEC source: 0001193125-25-325277 · ownership.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,391,922 F1 · price: The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased in multiple transactions at per share prices ranging from $8.12 to $8.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Includes (i)1,360,970 shares of Common Stock and (ii) 30,952 restricted stock units which are subject to vesting as previously reported. Read SEC document |
| June 06, 2025 Filed Jun 7, 2025 01:10 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 27,900 | $4.22 | $117,738.00 |
DisclosureSEC source: 0000950170-25-083413 · ownership.xml · nonDerivative · entry 4 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,377,964 F4 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at per share prices ranging from $4.20 to $4.245 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F5 · balance_after: Includes (i) 1,347,012 shares of Common Stock, and (ii) 30,952 restricted stock units which are subject to vesting as reported herein. Read SEC document |
| June 05, 2025 Filed Jun 7, 2025 01:10 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 30,952 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083413 · ownership.xml · nonDerivative · entry 3 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,350,064 F3 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of Common Stock. The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 5, 2025. The RSUs vest on the earlier of June 5, 2026 and the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. Read SEC document |
| June 05, 2025 Filed Jun 7, 2025 01:10 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 40,951 | $4.24 | $173,796.04 |
DisclosureSEC source: 0000950170-25-083413 · ownership.xml · nonDerivative · entry 2 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,319,112 F2 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at per share prices ranging from $4.19 to $4.295 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2025 Filed Jun 7, 2025 01:10 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 21,674 | $4.17 | $90,423.93 |
DisclosureSEC source: 0000950170-25-083413 · ownership.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,278,161 F1 · price: The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased in multiple transactions at per share prices ranging from $4.067 to $4.23 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 01:57 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 25,230 | $3.97 | $100,087.41 |
DisclosureSEC source: 0000950170-25-081367 · ownership.xml · nonDerivative · entry 3 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,256,487 F3 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at per share prices ranging from $3.85 to $4.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F4 · balance_after: Includes (i) 1,239,121 shares of Common Stock and (ii) 17,366 restricted stock units, which are subject to vesting as previously reported. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 01:57 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 30,799 | $3.88 | $119,438.52 |
DisclosureSEC source: 0000950170-25-081367 · ownership.xml · nonDerivative · entry 2 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,231,257 F2 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at per share prices ranging from $3.65 to $3.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 30, 2025 Filed Jun 4, 2025 01:57 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 42,753 | $3.67 | $156,903.51 |
DisclosureSEC source: 0000950170-25-081367 · ownership.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,200,458 F1 · price: The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased in multiple transactions at per share prices ranging from $3.505 to $3.715 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 29, 2025 Filed May 30, 2025 01:31 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 60,128 | $3.59 | $215,739.26 |
DisclosureSEC source: 0000950170-25-079292 · ownership.xml · nonDerivative · entry 3 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,157,705 F3 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at per share prices ranging from $3.50 to $3.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F4 · balance_after: Includes (i) 1,140,339 shares of Common Stock and (ii) 17,366 restricted stock units, which are subject to vesting as previously reported. Read SEC document |
| May 28, 2025 Filed May 30, 2025 01:31 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 26,715 | $3.52 | $93,929.94 |
DisclosureSEC source: 0000950170-25-079292 · ownership.xml · nonDerivative · entry 2 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,097,577 F2 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at per share prices ranging from $3.325 to $3.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 27, 2025 Filed May 30, 2025 01:31 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 41,346 | $3.44 | $142,064.86 |
DisclosureSEC source: 0000950170-25-079292 · ownership.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,070,862 F1 · price: The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased in multiple transactions at per share prices ranging from $3.29 to $3.46 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 12, 2025 Filed Mar 13, 2025 23:22 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | OtherCommon Stock | 243,000 | $2.77 | $673,110.00 |
DisclosureSEC source: 0000950170-25-039010 · ownership.xml · nonDerivative · entry 3 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 5,086,920 F1 · kind: These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President and sole director of Allegro Investment Inc., which is the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund for purposes of Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"). However, the Reporting Person does not have any pecuniary interest in the shares held by Allegro Investment Fund and disclaims beneficial ownership with respect to all such shares. Accordingly, this report is being provided voluntarily by the Reporting Person for informational purposes only and shall not be deemed an admission that the Reporting Person is the beneficial owner of any such shares for purposes of Section 16 under the Exchange Act or for any other purpose. F4 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at per share prices ranging from $2.665 to $2.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F1 · ownership.nature: These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President and sole director of Allegro Investment Inc., which is the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund for purposes of Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"). However, the Reporting Person does not have any pecuniary interest in the shares held by Allegro Investment Fund and disclaims beneficial ownership with respect to all such shares. Accordingly, this report is being provided voluntarily by the Reporting Person for informational purposes only and shall not be deemed an admission that the Reporting Person is the beneficial owner of any such shares for purposes of Section 16 under the Exchange Act or for any other purpose. Read SEC document |
| March 11, 2025 Filed Mar 13, 2025 23:22 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | OtherCommon Stock | 150,000 | $2.71 | $406,500.00 |
DisclosureSEC source: 0000950170-25-039010 · ownership.xml · nonDerivative · entry 2 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,843,920 F1 · kind: These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President and sole director of Allegro Investment Inc., which is the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund for purposes of Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"). However, the Reporting Person does not have any pecuniary interest in the shares held by Allegro Investment Fund and disclaims beneficial ownership with respect to all such shares. Accordingly, this report is being provided voluntarily by the Reporting Person for informational purposes only and shall not be deemed an admission that the Reporting Person is the beneficial owner of any such shares for purposes of Section 16 under the Exchange Act or for any other purpose. F3 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at per share prices ranging from $2.465 to $2.875 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F1 · ownership.nature: These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President and sole director of Allegro Investment Inc., which is the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund for purposes of Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"). However, the Reporting Person does not have any pecuniary interest in the shares held by Allegro Investment Fund and disclaims beneficial ownership with respect to all such shares. Accordingly, this report is being provided voluntarily by the Reporting Person for informational purposes only and shall not be deemed an admission that the Reporting Person is the beneficial owner of any such shares for purposes of Section 16 under the Exchange Act or for any other purpose. Read SEC document |
| March 10, 2025 Filed Mar 13, 2025 23:22 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | OtherCommon Stock | 120,000 | $2.53 | $303,600.00 |
DisclosureSEC source: 0000950170-25-039010 · ownership.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,693,920 F1 · kind: These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President and sole director of Allegro Investment Inc., which is the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund for purposes of Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"). However, the Reporting Person does not have any pecuniary interest in the shares held by Allegro Investment Fund and disclaims beneficial ownership with respect to all such shares. Accordingly, this report is being provided voluntarily by the Reporting Person for informational purposes only and shall not be deemed an admission that the Reporting Person is the beneficial owner of any such shares for purposes of Section 16 under the Exchange Act or for any other purpose. F2 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at per share prices ranging from $2.455 to $2.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F1 · ownership.nature: These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President and sole director of Allegro Investment Inc., which is the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund for purposes of Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"). However, the Reporting Person does not have any pecuniary interest in the shares held by Allegro Investment Fund and disclaims beneficial ownership with respect to all such shares. Accordingly, this report is being provided voluntarily by the Reporting Person for informational purposes only and shall not be deemed an admission that the Reporting Person is the beneficial owner of any such shares for purposes of Section 16 under the Exchange Act or for any other purpose. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 02:12 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 551,802 | $3.73 | $2,058,221.46 |
DisclosureSEC source: 0000950170-24-129885 · ownership.xml · nonDerivative · entry 2 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 4,573,920 F2 · balance_after: Includes 551,802 shares of Common Stock previously held directly by the Trust, which were sold to Allegro Investment Fund, L.P. ("Allegro Investment Fund") as reported herein. F3 · ownership.nature: These shares of Common Stock are held of record by Allegro Investment Fund. The Reporting Person is the President of Allegro Investment Inc., the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund. The Reporting Person disclaims beneficial ownership of the shares held by Allegro Investment Fund (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 02:12 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 551,802 | $3.73 | $2,058,221.46 |
DisclosureSEC source: 0000950170-24-129885 · ownership.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 632,456 F1 · ownership.nature: These shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), are held of record by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust (the "Trust"). The Reporting Person is a trustee of the Trust and may be deemed to beneficially own the shares held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 23:30 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 17,366 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071516 · ownership.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,029,516 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $120,000 divided by the closing price of the Common Stock on the grant date, June 6, 2024. The RSUs vest on the earlier of June 6, 2025 and the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. F2 · balance_after: Includes (i) 1,012,150 shares of Common Stock and (ii) 17,366 RSUs, which are subject to vesting as reported herein. Read SEC document |
| November 30, 2023 Filed Dec 2, 2023 00:39 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 140,777 | $3.46 | $486,637.93 |
DisclosureSEC source: 0000950170-23-067435 · ownership.xml · nonDerivative · entry 2 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,012,150 F1 · price: Reflects the weighted average price at which these shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased. The shares were purchased in multiple transactions at prices ranging from $3.38 to $3.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 15,094 restricted stock units ("RSUs") granted to the Reporting Person on June 8, 2023 under the Issuer's Non-Employee Director Compensation Program, which are subject to vesting as previously reported. Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| November 29, 2023 Filed Dec 2, 2023 00:39 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 3,223 | $3.50 | $11,280.50 |
DisclosureSEC source: 0000950170-23-067435 · ownership.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 871,373 Read SEC document |
| November 28, 2023 Filed Nov 29, 2023 01:32 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 253,669 | $3.46 | $877,136.67 |
DisclosureSEC source: 0000950170-23-066532 · ownership.xml · nonDerivative · entry 3 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 868,150 F3 · price: Reflects the weighted average price at which these shares of Common Stock were purchased. The shares were purchased in multiple transactions at prices ranging from $3.275 to $3.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F4 · balance_after: Includes 15,094 restricted stock units ("RSUs") granted to the Reporting Person on June 8, 2023 under the Issuer's Non-Employee Director Compensation Program, which are subject to vesting as previously reported. Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 01:32 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 246,331 | $3.31 | $815,946.80 |
DisclosureSEC source: 0000950170-23-066532 · ownership.xml · nonDerivative · entry 2 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 614,481 F2 · price: Reflects the weighted average price at which these shares of Common Stock were purchased. The shares were purchased in multiple transactions at prices ranging from $3.035 to $3.355, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 24, 2023 Filed Nov 29, 2023 01:32 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 21,855 | $3.09 | $67,427.05 |
DisclosureSEC source: 0000950170-23-066532 · ownership.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,150 F1 · price: Reflects the weighted average price at which these shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased. The shares were purchased in multiple transactions at prices ranging from $2.96 to $3.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 22, 2023 Filed Nov 22, 2023 23:19 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 41,085 | $2.50 | $102,708.39 |
DisclosureSEC source: 0000950170-23-065919 · ownership.xml · nonDerivative · entry 3 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,295 F3 · price: Reflects the weighted average price at which these shares of Common Stock were purchased. The shares were purchased in multiple transactions at prices ranging from $2.495 to $2.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F4 · balance_after: Includes 15,094 restricted stock units ("RSUs") granted to the Reporting Person on June 8, 2023 under the Issuer's Non-Employee Director Compensation Program, which are subject to vesting as previously reported.Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| November 21, 2023 Filed Nov 22, 2023 23:19 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 68,477 | $2.48 | $169,535.36 |
DisclosureSEC source: 0000950170-23-065919 · ownership.xml · nonDerivative · entry 2 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,210 F2 · price: Reflects the weighted average price at which these shares of Common Stock were purchased. The shares were purchased in multiple transactions at prices ranging from $2.34 to $2.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 23:19 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 79,234 | $2.25 | $178,189.34 |
DisclosureSEC source: 0000950170-23-065919 · ownership.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,733 F1 · price: Reflects the weighted average price at which these shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased. The shares were purchased in multiple transactions at prices ranging from $2.225 to $2.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 02:45 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 126,664 | $2.19 | $277,292.83 |
DisclosureSEC source: 0000950170-23-065273 · ownership.xml · nonDerivative · entry 2 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,499 F1 · price: Reflects the weighted average price at which the shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), were purchased. The shares were purchased in multiple transactions at prices ranging from $2.09 to $2.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 15,094 restricted stock units ("RSUs") granted to the Reporting Person on June 8, 2023 under the Issuer's Non-Employee Director Compensation Program (the "Program"), which are subject to vesting as previously reported. Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 02:45 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 339 | $2.00 | $678.00 |
DisclosureSEC source: 0000950170-23-065273 · ownership.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,835 Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 22:44 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 3,462 | $2.00 | $6,913.61 |
DisclosureSEC source: 0000950170-23-064582 · ownership.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,496 F1 · ownership.direct: Includes 15,094 restricted stock units ("RSUs") granted to the Reporting Person on June 8, 2023 under the Issuer's Non-Employee Director Compensation Program (the "Program") as previously reported. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:44 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 15,094 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015385 · doc4.xml · nonDerivative · entry 2 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,940 F2 · shares: Reflects a grant of RSUs made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of Common Stock. The number of RSUs granted is equal to approximately $120,000 of shares of Common Stock as determined by the closing price on the grant date, June 8, 2023. The RSUs vest on the earlier of June 8, 2024 and the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:44 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 11,940 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015385 · doc4.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,940 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person on June 8, 2022 under the Issuer's Non-Employee Director Compensation Program, as reported in Table II on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on August 5, 2022. Each RSU represented a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The RSUs vested in full on June 8, 2023. Read SEC document |
| June 08, 2023 Filed Nov 16, 2023 22:35 UTC Amendment | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 15,094 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-064579 · ownership.xml · nonDerivative · entry 2 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,034 F2 · shares: Reflects a grant of RSUs made to the Reporting Person under the Program. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest on the earlier of June 8, 2024 and the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Issuer's board of directors through such vesting date. Read SEC document |
| June 08, 2023 Filed Nov 16, 2023 22:35 UTC Amendment | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 11,940 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-064579 · ownership.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,940 F1 · shares: Reflects the vesting in full of 11,940 restricted stock units ("RSUs") granted to the Reporting Person on June 8, 2022 under the Issuer's Non-Employee Director Compensation Program (the "Program"), as reported in Table II on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on August 5, 2022. Each RSU represented a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). Read SEC document |
| June 08, 2022 Filed Aug 5, 2022 20:14 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantRestricted Stock Units · Derivative | 11,940 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-027828 · doc4.xml · derivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,940 Underlying: Common Stock · 11,940 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest on the earlier of (i) June 8, 2023 and (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date. The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs vest on the earlier of (i) June 8, 2023 and (ii) one day prior to the Company's 2023 annual meeting of shareholders, subject to the Reporting Person's continued service with the Issuer through such vesting date. The RSUs have no expiration date. Read SEC document |
| May 17, 2022 Filed May 18, 2022 01:40 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 250,000 | $8.49 | $2,123,725.00 |
DisclosureSEC source: 0000899243-22-018500 · doc4.xml · nonDerivative · entry 3 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 551,802 F2 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4) and (5). F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.155 to $8.73 per share, inclusive. F3 · ownership.nature: These shares are held of record by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust (the "Trust"). The Reporting Person is a trustee of the Trust and may be deemed to beneficially own the shares held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 16, 2022 Filed May 18, 2022 01:40 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 300,000 | $8.20 | $2,460,000.00 |
DisclosureSEC source: 0000899243-22-018500 · doc4.xml · nonDerivative · entry 2 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 301,802 F2 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4) and (5). F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.025 to $8.45 per share, inclusive. F3 · ownership.nature: These shares are held of record by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust (the "Trust"). The Reporting Person is a trustee of the Trust and may be deemed to beneficially own the shares held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 13, 2022 Filed May 18, 2022 01:40 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 1,802 | $7.98 | $14,381.94 |
DisclosureSEC source: 0000899243-22-018500 · doc4.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,802 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.91 to $8.00 per share, inclusive. F2 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4) and (5). F3 · ownership.nature: These shares are held of record by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust (the "Trust"). The Reporting Person is a trustee of the Trust and may be deemed to beneficially own the shares held by the Trust. The Reporting Person disclaims beneficial ownership of the shares held by the Trust (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 02:27 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 62,959 | $22.92 | $1,443,020.28 |
DisclosureSEC source: 0000899243-21-046456 · doc4.xml · nonDerivative · entry 8 Encrantz Staffan · CIK 0001870875 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,022,118 F2 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (5), (6), (7), (8) , (9) and (10). F10 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.835 to $22.975, inclusive. F3 · ownership.nature: These shares are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President of Allegro Investment Inc., the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund. The Reporting Person disclaims beneficial ownership of the shares held by Allegro Investment Fund (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 02:27 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 123,931 | $22.36 | $2,771,097.16 |
DisclosureSEC source: 0000899243-21-046456 · doc4.xml · nonDerivative · entry 7 Encrantz Staffan · CIK 0001870875 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,959,159 F2 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (5), (6), (7), (8) , (9) and (10). F9 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.835 to $22.83, inclusive. F3 · ownership.nature: These shares are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President of Allegro Investment Inc., the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund. The Reporting Person disclaims beneficial ownership of the shares held by Allegro Investment Fund (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 02:27 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 27,716 | $21.43 | $593,953.88 |
DisclosureSEC source: 0000899243-21-046456 · doc4.xml · nonDerivative · entry 6 Encrantz Staffan · CIK 0001870875 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,835,228 F2 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (5), (6), (7), (8) , (9) and (10). F8 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.83 to $21.82, inclusive. F3 · ownership.nature: These shares are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President of Allegro Investment Inc., the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund. The Reporting Person disclaims beneficial ownership of the shares held by Allegro Investment Fund (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 02:27 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 56,836 | $20.96 | $1,191,282.56 |
DisclosureSEC source: 0000899243-21-046456 · doc4.xml · nonDerivative · entry 5 Encrantz Staffan · CIK 0001870875 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,807,512 F2 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (5), (6), (7), (8) , (9) and (10). F7 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.85 to $21.00, inclusive. F3 · ownership.nature: These shares are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President of Allegro Investment Inc., the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund. The Reporting Person disclaims beneficial ownership of the shares held by Allegro Investment Fund (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 02:27 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 94,969 | $20.40 | $1,937,367.60 |
DisclosureSEC source: 0000899243-21-046456 · doc4.xml · nonDerivative · entry 4 Encrantz Staffan · CIK 0001870875 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,750,676 F2 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (5), (6), (7), (8) , (9) and (10). F6 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.84 to $20.825, inclusive. F3 · ownership.nature: These shares are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President of Allegro Investment Inc., the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund. The Reporting Person disclaims beneficial ownership of the shares held by Allegro Investment Fund (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 02:27 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 72,135 | $19.44 | $1,402,304.40 |
DisclosureSEC source: 0000899243-21-046456 · doc4.xml · nonDerivative · entry 3 Encrantz Staffan · CIK 0001870875 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,655,707 F2 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (5), (6), (7), (8) , (9) and (10). F5 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.80 to $19.79, inclusive. F3 · ownership.nature: These shares are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President of Allegro Investment Inc., the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund. The Reporting Person disclaims beneficial ownership of the shares held by Allegro Investment Fund (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 29, 2021 Filed Dec 2, 2021 02:27 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 2,200 | $19.06 | $41,932.00 |
DisclosureSEC source: 0000899243-21-046456 · doc4.xml · nonDerivative · entry 2 Encrantz Staffan · CIK 0001870875 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,583,572 F2 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (5), (6), (7), (8) , (9) and (10). F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.05 to $19.06, inclusive. F3 · ownership.nature: These shares are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President of Allegro Investment Inc., the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund. The Reporting Person disclaims beneficial ownership of the shares held by Allegro Investment Fund (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| November 29, 2021 Filed Dec 2, 2021 02:27 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 84,254 | $18.84 | $1,587,345.36 |
DisclosureSEC source: 0000899243-21-046456 · doc4.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,581,372 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.05 to $19.03, inclusive. F2 · price: The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (4), (5), (6), (7), (8) , (9) and (10). F3 · ownership.nature: These shares are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President of Allegro Investment Inc., the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund. The Reporting Person disclaims beneficial ownership of the shares held by Allegro Investment Fund (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| October 18, 2021 Filed Oct 21, 2021 00:30 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | PurchaseCommon Stock | 527,048 | $24.00 | $12,649,152.00 |
DisclosureSEC source: 0000899243-21-040878 · doc4.xml · nonDerivative · entry 1 Encrantz Staffan · CIK 0001870875 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,497,118 F1 · kind: On September 2, 2021, the Reporting Person entered into a Stock Purchase Agreement to acquire these shares. All material conditions to the completion of the purchase were satisfied as of October 18, 2021. The closing of the stock purchase has not yet occurred. F1 · shares: On September 2, 2021, the Reporting Person entered into a Stock Purchase Agreement to acquire these shares. All material conditions to the completion of the purchase were satisfied as of October 18, 2021. The closing of the stock purchase has not yet occurred. F2 · ownership.nature: These shares are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President of Allegro Investment Inc., the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund. The Reporting Person disclaims beneficial ownership of the shares held by Allegro Investment Fund (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 00:16 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | ConversionSeries C Redeemable Convertible Preferred Stock · Derivative | 316,228 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-028879 · doc4.xml · derivative · entry 6 Encrantz Staffan · CIK 0001870875 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 632,456 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: This series of preferred stock has no expiration date and automatically converted into common stock on a 2 for 1 basis upon the closing of the Issuer's initial public offering. F3 · price: This series of preferred stock has no expiration date and automatically converted into common stock on a 2 for 1 basis upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: This series of preferred stock has no expiration date and automatically converted into common stock on a 2 for 1 basis upon the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: This series of preferred stock has no expiration date and automatically converted into common stock on a 2 for 1 basis upon the closing of the Issuer's initial public offering. F2 · ownership.nature: These shares are held of record by Allegro Investors LLC ("Allegro Investors"). The Reporting Person is a member of Allegro Investors and may be deemed to beneficially own the shares held by Allegro Investors. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 00:16 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | ConversionSeries C Redeemable Convertible Preferred Stock · Derivative | 661,653 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-028879 · doc4.xml · derivative · entry 5 Encrantz Staffan · CIK 0001870875 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,323,306 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: This series of preferred stock has no expiration date and automatically converted into common stock on a 2 for 1 basis upon the closing of the Issuer's initial public offering. F3 · price: This series of preferred stock has no expiration date and automatically converted into common stock on a 2 for 1 basis upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: This series of preferred stock has no expiration date and automatically converted into common stock on a 2 for 1 basis upon the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: This series of preferred stock has no expiration date and automatically converted into common stock on a 2 for 1 basis upon the closing of the Issuer's initial public offering. F1 · ownership.nature: These shares are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President of Allegro Investment Inc., the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund. The Reporting Person disclaims beneficial ownership of the shares held by Allegro Investment Fund (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 19, 2021 Filed Jul 20, 2021 00:16 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | ConversionSeries B Redeemable Convertible Preferred Stock · Derivative | 98,745 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-028879 · doc4.xml · derivative · entry 4 Encrantz Staffan · CIK 0001870875 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 197,490 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: This series of preferred stock has no expiration date and automatically converted into common stock on a 2 for 1 basis upon the closing of the Issuer's initial public offering. F3 · price: This series of preferred stock has no expiration date and automatically converted into common stock on a 2 for 1 basis upon the closing of the Issuer's initial public offering. F3 · derivative.exercise_date: This series of preferred stock has no expiration date and automatically converted into common stock on a 2 for 1 basis upon the closing of the Issuer's initial public offering. F3 · derivative.expiration_date: This series of preferred stock has no expiration date and automatically converted into common stock on a 2 for 1 basis upon the closing of the Issuer's initial public offering. F1 · ownership.nature: These shares are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the President of Allegro Investment Inc., the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund. The Reporting Person disclaims beneficial ownership of the shares held by Allegro Investment Fund (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose), except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.